Category: 355806-00-7

As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, molecular formula is C26H36FN3O6S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. name: (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example 7- (Preparation in ACN/H20) A 250ML flask equipped with a mechanical stirrer was charged with ACN (25 mL), t- Butyl-Rosuvastatin (5 g), H20 (25 mL) and NAOH pellets (1. 86G). The mixture was stirred at ambient temperature for 2 hours. The phases were separated in a separating funnel. The aqueous phase was concentrated under reduced pressure to obtain an oily residue (12.0 g). To this residue was added water (40 ml) and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (overnight) to form a white precipitate. The organic phase was concentrated under reduced pressure to obtain an oily residue (13.0 g). To this residue were added 40 mL water and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (over night) to FORM a white precipitate. Both parts were filtered and washed with 10 mL of water to get a powdery compound. (0. 86 g from aqueous phase, 4.01 g from organic phase)

With the rapid development of chemical substances, we look forward to future research findings about 355806-00-7.

Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2005/23778; (2005); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of 355806-00-7, In the chemical reaction process,reaction time,type of solvent,can easily affect the result of the reaction, thereby determining the yield and properties of the reaction product.An updated downstream synthesis route of 355806-00-7 as follows.

Example 8- (Preparation in Toluene/H20) A 250ML flask equipped with a mechanical stirrer was charged with toluene (25 mL), 5 g t-Butyl-Rosuvastatin, 25 mL H20, 0.75 g of TBAB (tetrabutylammonium bromide) (15% W/W) and 1. 86 g NAOH pellets. The mixture was stirred at ambient temperature for 2 hours. The phases were separated in an apparatus funnel. Traces of toluene in the aqueous phase were distilled off under reduced pressure at 40C to obtain a thick slurry (36.0 g). To this slurry was added 49.5 g CaCl2 1N dropwise. The solution was stirred at ambient temperature for 1.5 hours, filtered and washed with 10 mL of water to get a powdery compound.; Example 10- (preparation in Toluene/H20, 5EQ NAOH)) A 250ML flask equipped with a mechanical stirrer was charged with toluene (25 mL), 5 g t-Butyl-Rosuvastatin, 25 mL H2O, 0.75 g TBAB (tetrabutylammonium bromide) (15% w/w) and 1.86 g NAOH pellets. The mixture was stirred at ambient temperature for 2 hours. The phases were separated in a separation funnel. Traces of toluene in the aqueous phase were distilled off under reduced pressure at 40C to obtain a slurry (24.0 g). Make-up of water was done (26 mL) at the end of the evaporation to obtain a clear solution. To this solution was added 3.3 g CaCl2 IN L0 ML water dropwise. The solution was stirred at ambient temperature for 2 hours, filtered and washed with LOML of water to get a powdery compound.

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route,355806-00-7, its application will become more common.

Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2005/23778; (2005); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Reference of 355806-00-7, The major producers of chemicals have been the Europe, Japan and China. Due to the growing call for a cleaner, greener environment, people will have to find innovative ways to maintain their relevance. Here is a compound 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester. This compound has unique chemical properties. The synthetic route is as follows.

Example 7; General procedure for preparing isolated ammonium salts of rosuvastatin; 5 g of terf-butyl ester of rosuvastatin 1.75 ml of 8 M NaOH 25 ml of demineralized water 10 ml of tetrahydrofuran EPO The reactants and the solvents are stirred from 50 to 55C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 50 ml methylcyclohexane yielding 33 ml of aqueous solution of sodium salt of rosuvastatin.To 33 ml of sodium rosuvastatinate solution prepared in the above described experiment is added 1.3 ml 85% phosphoric acid, previously dissolved in 5 ml of water. Reaction mixture is extracted with 40 ml of /so-butyl acetate. Organic layer is separated off and dried with 5 g of anhydrous magnesium sulphate. Drying agent is filtered off and washed with 10 ml /so-butyl acetate obtaining 52 ml of filtrate containing rosuvastatinic acid, which is divided into smaller portions for preparing various ammonium salts.To 5 ml of the obtained solution 1.5 equivalents of appropriate amine and 5 ml tert-butyl methyl ether are added. Rosuvastatin substituted ammonium salt is filtered off and dried on filter. The following solid salts are prepared:cyclohexylammonium salt of rosuvastatin: 0.45 g, 99.71% area by HPLC;1H-NMR: (CD3OD): 1.10 – 1.45 (12H,m), 1.31 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1 H,m), 1.80 – 1.87 (2H,m), 1.97 – 2.03 (2H,m), 2.25 (1H,dd, J1=MHz, J2=7.6Hz), 2.34 (1H,dd, J1=MHz1 J2=4.9Hz), 2.98 – 3.09 (1 H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1H,m), 5.56 (1 H,dd, J1=^Hz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1H,m);dicyclohexylammonim salt of rosuvastatin: 0.35 g, 99.82% area;1H-NMR: (CD3OD): 1.12 – 1.76 (20H,m), 1.29 (d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1H,m), 1.83 – 1.92 (4H,m), 2.01 – 2.09(4H,m), 2.25 (1H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4.9Hz), 3.07 – 3.17 (2H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J,=16Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7,75 (2H,m);pyrrolidinium salt of rosuvastatin: 0.28 g, 99.71% area,1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1H,m), 1.96 – 2.01 (4H,m), 2.25 (1H,dd, J1=MHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4,9Hz), 3.20 – 3.25 (4H,m), 3,51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1 H,m), 4.33 – 4.40 EPO (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=IeHz, J2=1 ,2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (2H,m);piperidinium salt of rosuvastatin: 0.28 g, 99.77% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.81 (7H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2,34 (1 H,dd, J1=MHz, J2=4,9Hz), 3.09 – 3.13 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1 H,m), 5.56 (1 H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7,22 (1H,m), 7.69 – 7.75 (2H,m);morpholinium salt of rosuvastatin: 0.30 g, 99.51% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.49 – 1.57 (1 H,m), 1.62 – 1.72 (1H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2.34 (1 H,dd, J1=HHz, J2=4.9Hz), 3.12 – 3.16 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.53 (3H,s), 3.81 – 3.,85 (4H,m), 3.92 – 4.00 (1H,m), 4.33 – 4.40 (1H,m), 5.57 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=IeHz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1H,m);1-adamantylammonium salt of rosuvastatin: 0.66 g, 99.75% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.85 (16H,m), 2.15 (3H,s (broad)), 2.25 (1 H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=UHz, J2=4.9Hz), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1 H,m).; Example 8; Preparation of N-cyclohexylammonium salt of rosuvastatin; 1O g tert-butyl ester of rosuvastatin3.5 ml 8 M NaOH50 ml demineralized water20 ml tetrahydrofuran EPO The reactants and the solvents are stirred from 50 to 55C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 100 ml methylcyclohexane yielding 66 ml of aqueous solution of sodium rosuvastatinate.To 33 ml of the obtained solution is added 1.3 ml 85% phosphoric acid in 5 ml demineralized water. Rosuvastatinic acid is extracted with 40 ml /so-propyl acetate. 4.7 g of anhydrous magnesium sulphate and 0.5 g charcoal is added to organic phase and suspension is stirred for 45 min. Magnesium sulphate and charcoal are filtered off yielding 41 ml of filtrate.16 ml of the filtrate is separated and treated by addition of 0.5 ml of cyclohexylamine in 8 ml of /so-propyl acetate during stirring and rosuvastatin cyclohexylammonium salt precipitate instantaneously as white solid. It is separated by filtration, precipitate is washed on the filter with 10 ml of /so-propyl acetate and dried on the filter yielding 1.34 g of the de…

According to the analysis of related databases, 355806-00-7, the application of this compound in the production field has become more and more popular.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136407; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Adding a certain compound to certain chemical reactions, such as: 355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, Computed Properties of C26H36FN3O6S, blongs to pyrimidines compound. Computed Properties of C26H36FN3O6S

(2) Preparation of sodium (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxy-hept-6-enoate (compound IV) To a 5 L four-necked flask, 2 L (10 mL/g) of acetonitrile and 200 g (1 mol) of tert-butyl 6-[(1E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methanesulfonyl)amino]-5-pyrimidinyl]vinyl]-2,2-dimethyl-1,3-dioxane-4-acetate (compound III) were added, and stirred to homogeneity, followed by adding 14.8 g (0.02 mol, calculated from titrated content) of an aqueous solution of hydrochloric acid having a mass percentage concentration of 0.06%. The system was warmed up to 35 C. and stirred at the same temperature for 5 hours until compound III was completely consumed. To the reaction system was added dropwise 32.5 g (1.1 mol) of an aqueous solution of sodium hydroxide having a mass percentage concentration of 4%, and stirred at 20 C. for 7 hours until the dihydroxy ester intermediate produced in the first phase was completely consumed. The system was concentrated to remove acetonitrile, followed by adding 2 L (10 mL/g) of purified water, and stirred to clearness. The system was extracted three times with 400 mL (2 mL/g) of methyl tert-butyl ether. The aqueous phase was further concentrated until no organic solvent was left, to give the an aqueous solution of the product, sodium (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxy-hept-6-enoate (compound IV), with a purity of >98% and a yield of 97%.

At the same time, in my other blogs, there are other synthetic methods of this type of compound,355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, and friends who are interested can also refer to it.

Reference:
Patent; Asymchem Laboratories (Tianjin) Co., Ltd.; Asymchem Life Science (Tianjin) Co., Ltd.; Tianjin Asymchem Pharmaceutical Co., Ltd.; Asymchem Laboratories (Fuxin) Co., Ltd.; Jilin Asymchem Laboratories Co., Ltd.; HONG, Hao; GAGE, James; LI, Jiuyuan; SHEN, Litao; ZHANG, Lei; DONG, Changming; (12 pag.)US2017/22169; (2017); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of 355806-00-7, Researchers who often do experiments know that organic synthesis is a process of preparing more complex target molecules from simple raw materials through one or more chemical reactions. Generally, it requires fewer steps,and cheap raw materials. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester. A new synthetic method of this compound is introduced below.

In a three-necked flask with a condenser, rosuvastatin tert-butyl ester 50.0g, 12.0g (+/-) – phenethylamine and 130ml toluene, stirring for reaction at 100 ~ 110 degrees for about 12 hours, the reaction was complete after HPLC detection of raw materials, slightly cooled, was added 80ml of water, rhoEta = 5 with concentrated hydrochloric acid, points to the water layer, the oil layer was concentrated to dryness to give a reddish brown oil. In the above oil Added 250ml methyl tert-butyl ether, warmed to a clear, refluxed 10min, naturally cooled to 25-30 C, a large amount of white solid Precipitation, stirring crystallization 2h, filtered and dried, weighed 49.5g, a yield of 91.0% by liquid detection, the corresponding isomer is 0.18%

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route,355806-00-7, its application will become more common.

Reference:
Patent; Zhejiang Jingxin Pharmaceutical Co., Ltd.; Shangyu Jing Xin Pharmaceutical Co., Ltd.; Zhu Jianrong; Zhong Hongban; Zhang Zhongliang; Wang Faping; Chen Jianyang; (8 pag.)CN104529908; (2017); B;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Adding a certain compound to certain chemical reactions, such as: 355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, Recommanded Product: 355806-00-7, blongs to pyrimidines compound. Recommanded Product: 355806-00-7

Example 1; Preparation of rosuvastatin calcium salt via rosuvastatin sodium salt solution; Rosuvastatin te/f-butyl ester (60.0 g, 111.6 mmol) is dissolved in 500 mL of a 4:1 mixture of THF / water. The clear solution is warmed to 30 0C and 8.0 M NaOH (15 mL, 120.0 mmol) is added portionwise. The reaction mixture is stirred at 30 X for 2 hours giving a clear yellow solution. Then THF is removed completely under the reduced pressure (20 mbar) at 40 0C. The remaining aqueous solution is diluted with water to 500 mL and washed with AcOEt (2*200 mL). After separation from the organic layer aqueous phase is distilled under the reduced pressure (20 mbar) at 40 0C to completely remove the dissolved AcOEt. The remaining clear solution of sodium rosuvastatinate (440 mL) is diluted with water (60 mL) to 500 mL and warmed to 40 0C. To a vigorously stirring solution of sodium rosuvastatinate is added dropwise Ca(OAc)2chiH2theta (14.8 g, 84.0 mmol in 60 mL of water) over 5 minutes at 40 0C to precipitate rosuvastatin calcium. After the complete addition the suspension is stirred further for 30 minutes at 40 0C. The white precipitate is filtered off. Then a wet white solid is suspended in water (200 mL) and vigorously stirred for 1 hour at 20 0C. The undissolved precipitate is collected by filtration, washed with water (200 mL) and dried in vacuum at 40 0C to give 48.5 g (86.8 %) of rosuvastatin calcium salt as white powder (HPLC: 99.87 %).; Example 2; Rosuvastatin terf-butyl ester (60.0 g, 111.6 mmol) is dissolved in 120 mL of tetrahydrofuran (THF) and 300 ml of water treated 8.0 M NaOH (21 mL) is added portionwise. The reaction mixture is stirred at 5O0C for 2 hours. Reaction mixture is allowed to cool to room temperature and washed with 2 x 540 ml of methylcyclohexane. EPO Aqueous phase is evaporated at 600C under reduced pressure to 220 ml of total volume to eliminate organic solvents. The residue obtained is rediluted with degassed demi-water to 440 ml of total volume. To the resulting solution 1.0 g of charcoal is added and the suspension is stirred half an hour. Charcoal is filtered off. One half of the volume of the filtrate (220 ml of total 440 ml) 25.5 ml aqueous solution of calcium chloride (prepared from 10.5 ml 4M calcium chloride and 15 ml demi- water) is added during stirring on ice-bath. The suspension formed is treated vigorously with ultraturrax at cca 18000 rpm for 3 minutes. The precipitate is filtered off, suspended anew in 100 ml demi water and treated again with Ultraturax at 18000 rpm for 3 minutes on ice-bath. The product is separated by filtration, washed with 30 ml ice-cold degassed demi-water, collected from the filter and dried 12 hours at 500C in vacuum desiccator.Yield: 25.05 g of amorphous rosuvastatin calcium (99.75% area, HPLC, 0.085 % Na)The second aliquot of 220 ml of filtrate is treated on the same way except mechanical stirring instead of ultraturax mixing is performed. Yield 25.11 g (99.72% area, HPLC, 1.55 % Na); Example 3; Rosuvastatin fe/f-butyl ester (10.0 g) is dissolved in 20 mL of tetrahydrofuran and 50 ml of water treated 8.0 M NaOH (3.51 mL) is added portionwise. The reaction mixture is stirred at 500C for 1 hours. One third (26 ml of the total 78 ml) of the resulting solution is washed with 35 ml methylcyclohexane. Methylcyclohexane phase is extracted with 3 ml demi water. Combined aqueous phases are washed with 20 ml /so-propyl acetate. Aqueous phase is then concentrated by evaporation under reduced pressure at 50C to 15 – 20 ml of total volume. It is cooled on ice-bath and gradually 1.1 ml aqueous solution of 4M calcium chloride is added within a minute during stirring. It is stirred additional 30 minutes on ice-bath and the precipitated product is separated by filtration. The precipitate is washed with 4.0 ml demi water, EPO collected from the filter and dried at room temperature 12 hours in vacuum desiccator.Yield: 2.22 g of amorphous rosuvastatin calcium.Two further aliquots are washed with 20 ml ethyl acetate or 20 ml terf-butyl methyl ether respectively with similar yield and quality.; Example 4; Preparation of rosuvastatin sodium salt; Rosuvastatin fe/-butyl ester (3.0 g, 5.6 mmol) is dissolved in 25 mL of a 4:1 mixture of THF / water. The clear solution is warmed to 30 0C and 8.0 M NaOH (0.75 mL, 6.0 mmol) was added portionwise. The reaction mixture is stirred at 30 0C for 2 hours giving a clear yellow solution. Then THF is removed completely under the reduced pressure (20 mbar) at 40 0C. The remaining aqueous solution is diluted with water to 25 mL and washed with AcOEt (2×10 mL). After separation from the organic layer aqueous phase is distilled under the reduced pressure (20 mbar) at 40 0C to completely remove the dissolved AcOEt. The remaining clear solution of sodium rosuvastatinate is diluted with water to 25 mL and liophylized to afford 2.81 g (100 %) of rosuvastatin sodium salt as white powder.; Example 8; Preparation of solid rosuva…

At the same time, in my other blogs, there are other synthetic methods of this type of compound,355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, and friends who are interested can also refer to it.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136408; (2006); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, molecular formula is C26H36FN3O6S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. Application In Synthesis of (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example-2:40 g of Rosuvastatin diol ester as prepared in example-1 above was taken in 400 mL of methanol at 25C to 35nC and cooled to 20″-25″C. The mixture of sodium hydroxide (3.6 g) and water (72 mL) solution was added to above solution within 30 minutes. After complete addition, the solution was stirred and further cooled to 10- 200C. The pH was adjusted between 7.5-8.5 by IN HCl (17 mL). Remaining mixture was washed with toluene at 20 to 300C. The aqueous layer was subjected to distillation under vacuum to remove MeOH below 500C till remaining volume becomes 130 mL. The volume was adjusted to 250 mL by adding water. The remaining mixture was passed through hydrobed and washed with water. A solution of 10.3 g calcium chloride in 40 mL water was added to the reaction mixture and the solution was filtered at 150C to 200C. The temperature was raised upto 250C to 35C and stirred for 1 hr. The product was filtered and washed with water. The product was dried at 500C to 55C to get 34.7 g of Rosuvastatin Calcium having individual impurity less than 0.1% HPLC Purity > 99.65% .

With the rapid development of chemical substances, we look forward to future research findings about 355806-00-7.

Reference:
Patent; CADILA HEALTHCARE LIMITED; WO2007/99561; (2007); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Each compound has different characteristics, and only by selecting the characteristics of the compound suitable for a specific situation can the compound be applied on a large scale. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester. This compound has unique chemical properties. The synthetic route is as follows. Quality Control of (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example 1; Hydrolysis of terf-butyl ester of rosuvastatin in aqueous solution of amines; 7.5 g of terf-butyl ester of rosuvastatin 38 ml of demineralized water 2 to 5 equivalents of amineThe reactants and water as the solvent are stirred in the autoclave from 98 to 1000C for 1 to 4 hours. The reaction mixture is sampled and analyzed by HPLC (“High Pressure Liquid Chromatography”) to find out the completion of reaction. Results are shown in Table 1. EPO

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it, 355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136407; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Each compound has different characteristics, and only by selecting the characteristics of the compound suitable for a specific situation can the compound be applied on a large scale. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester. This compound has unique chemical properties. The synthetic route is as follows. Quality Control of (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example 1; Hydrolysis of terf-butyl ester of rosuvastatin in aqueous solution of amines; 7.5 g of terf-butyl ester of rosuvastatin 38 ml of demineralized water 2 to 5 equivalents of amineThe reactants and water as the solvent are stirred in the autoclave from 98 to 1000C for 1 to 4 hours. The reaction mixture is sampled and analyzed by HPLC (“High Pressure Liquid Chromatography”) to find out the completion of reaction. Results are shown in Table 1. EPO

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it, 355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136407; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Adding a certain compound to certain chemical reactions, such as: 355806-00-7, (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, Quality Control of (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, blongs to pyrimidines compound. Quality Control of (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example 3; Hydrolysis of terf-butyl ester of rosuvastatin in a solution of strong organic nitrogen bases; The solution of terf-butyl ester of rosuvastatin in a mixture of a base, tetrahydrofuran and water in the ratio of 1:6:15 by volume is stirred at 50C for few hours. The reaction mixture is sampled and analysed by HPLC to find out the completion of reaction. Results are shown in Table 2. EPO

The synthetic route of 355806-00-7 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136407; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia